Articles tagged with Cell Therapies
A team of scientists from Helmholtz Zentrum München has isolated and characterized therapy-resistant leukemia cells, which are responsible for relapse in the disease. These cells can be eliminated using modern genetic engineering techniques, offering a new approach to prevent disease relapse.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
In a phase 1 clinical study of 32 participants with advanced B cell non-Hodgkin lymphoma, immunotherapy with defined subsets of T cells showed strong antitumor activity. The therapy was found to be more effective when combined with specific ratios of CD4 and CD8 CAR-T cells and pretreatment chemotherapy regimen.
A new cell therapy product called DUOC-01 promotes faster axon remyelination in mice treated with a demyelinating chemical agent. The treatment also enhances the differentiation of oligodendrocyte progenitor cells, suggesting potential for neuronal repair and remyelination in patients with demyelinating diseases.
A new approach using metabolic imaging could help determine a patient's response to targeted therapies much earlier and with greater precision than traditional tumor shrinkage. This method recognizes a drug's ability to stop cancer cells' energy overuse, allowing for more accurate assessments of treatment success.
A new study has found a way to starve tumors of their blood supply by inhibiting the replenishment of an intracellular substrate needed for vascular endothelial cells to respond to pro-angiogenic signals. This approach limits the growth of new blood vessels and enhances the effectiveness of therapy.
Researchers develop new method to generate large pool of gene-corrected cells, which can repopulate in vivo and treat various disorders
Researchers developed a dual nanoparticle delivery system for piperlongumine and TRAIL, demonstrating increased therapeutic efficacy in vitro and in vivo. The system sensitizes cancer cells to TRAIL, leading to higher apoptotic rates and improved anti-cancer effects.
Researchers at KARBio LLC and Genentech Inc. discovered that targeting human CRTh2 (hCRTh2) depletes immune cells implicated in asthma-associated inflammation, reducing cytokine production and lung inflammation in asthmatic mice. The study's findings support further exploration of hCRTh2 as a therapeutic target for asthma treatment.
Autologous cardiac cells, particularly atrial appendage-derived cells, show promise for gene and RNA therapies in heart failure. The review discusses financial and authority-based restrictions influencing research in this field, highlighting the potential of autologous tissues as cell therapy sources.
Researchers at VIB-UGent demonstrate that adult circulating monocytes can differentiate into macrophages with identical tissue-specific functions and self-maintenance capacities as those from embryonic origin. This discovery paves the way for monocyte-based cellular therapy in diseases associated with macrophage dysfunction, such as pu...
Researchers found that dozens of targeted therapies inhibit T cell activity, which can help fight tumors. However, pairing these drugs with an IL-15 superagonist stimulates T cell activity, preserving cancer-blocking effects. The study suggests a potential way to overcome immunosuppressive effects while maintaining anti-cancer benefits.
Recent advances in T cell therapy have brought the idea of fighting chronic infections and cancers closer to reality. The use of potent cells with a safety mechanism has been demonstrated, and clinical trials have yielded highly promising results.
A recent study by McGill University researchers has made significant progress in understanding the mechanisms responsible for multiple sclerosis and identifying potential new treatments. By targeting a subset of B cells known as GM-CSF-producing B cells, the therapy shows promise in reducing disease activity.
Researchers at Griffith University have developed a new technique for growing cells in three dimensions, allowing them to freely associate and form natural structures. This method, using floating liquid marbles, has the potential to increase cell growth and function, particularly useful for spinal cord transplantation repair.
Kazan researchers compared direct gene and blood cell-mediated therapy for spinal cord injuries, revealing similar recovery outcomes in rats. The study found that both therapies preserved myelinated fibers, with cell-based therapy extending therapeutic influence over longer distances.
A clinical trial of a personalized cell therapy, CTL019, achieved an overall response rate of 57% and complete remissions in eight out of 14 patients with chronic lymphocytic leukemia (CLL). The therapy, developed by Penn researchers, involves reprogramming patients' own T cells to hunt and kill cancer cells.
Natural killer cells are impaired in the tumor microenvironment, but can be restored in normal conditions. Researchers identified two key factors blocking NK cell function: inflammatory cytokine IL-10 and down-regulated NKG2D ligands.
Researchers have successfully used autologous fat cell transplants to improve symptoms of osteoarthritis in patients. The treatment showed significant improvements in pain management and joint mobility, with most patients experiencing a minimum of 50% score improvement after 12 months.
A clinical trial found that patients who received more CD34+ bone marrow cells experienced significant benefits, with improved ejection fraction and lower rates of major adverse cardiac events. The study, which enrolled 161 patients, showed a dose-dependent trend in the effects of cell therapy on heart function.
Rapid lowering of body temperature after a heart attack can minimize damage to the heart muscle. New research highlights the need for faster and more effective cooling techniques to realize the full potential of therapeutic hypothermia.
A new technology developed by VIB/UGent scientists has simplified the production of biotech medicines by truncating complex sugar structures, retaining therapeutic efficiency. This innovation has the potential to make biotech medicine production cheaper and more efficient.
Researchers discovered that nimotuzumab promotes autophagic cell death, enhancing the antitumor effects of chemotherapy and radiation in ESCC cells with high EGFR expression. This finding suggests a potential strategy for improving therapeutic efficacy in esophageal squamous cell carcinoma.
Researchers discovered how Fragile X mental retardation protein affects brain cell protein production, leading to the development of potential therapies for the genetic disorder. The study identified a critical binding site on the ribosome that could be targeted by drugs.
Scientists have discovered a molecule that can induce cell death (apoptosis) in dendritic cells, a key type of immune cell. This understanding may lead to new therapies that shut down dendritic cell activity and reduce an immune reaction.
Researchers found therapeutic hypothermia to be beneficial for some patients following cardiac arrest, but ineffective or even worsening outcomes in others. The study suggests a need for more rigid guidelines to ensure appropriate application of cooling strategies.
New research reveals that macrophage populations mediate tumor cell removal following monoclonal antibody treatment. Additionally, targeting the p57Kip2 pathway in adults with type 2 diabetes may improve β cell function and expand β cell mass.
A new therapy for preventing production of sphingolipids in lymphoma cells has been developed, selectively killing virus-infected cells. The treatment, ABC294640, shows promise in treating primary effusion lymphoma, an aggressive variant of diffuse large B-cell lymphoma caused by viruses.
The university's premier biomedical instrument is expected to provide breakthroughs in treating animal and human health conditions, including cancer. The instrument uses thermal cell therapy and high-resolution imaging to target specific cells and tumors.
Researchers found that mild hypothermia improved behavioral scores and increased surviving neurons in rats with TBI. The treatment also reduced harmful protein levels linked to brain injury and cognitive dysfunction.
Researchers develop a therapeutic strategy that manipulates cellular heterogeneity to treat advanced melanoma. The approach uses a new drug-like molecule in combination with an existing chemotherapy, targeting only melanoma cells and suppressing tumor growth and metastasis.
Researchers have identified two key compounds produced by mast cells that promote fibrogenesis, leading to pulmonary fibrosis. Introducing mast cells into mice lungs can reverse disease protection and cause pulmonary fibrosis.
Researchers at VIB developed a mouse model to study the molecular mechanisms determining cellular identity, enabling targeted manipulation of iPS cells for safer and more effective therapies. This breakthrough advances cell therapy using iPS cells for regenerative medicine applications.
Research demonstrates that immune system's natural killer cells can kill off virus-infected tumor cells, rendering glioblastoma virotherapy less effective. The study suggests temporarily suppressing the immune system may counteract this response and enhance therapy.
Researchers from Ruhr-University Bochum report that impaired protein degradation causes muscle diseases, including filaminopathies. The study found that protection mechanisms against abnormal protein deposits do not work properly in patients, opening up new avenues for therapies.
The new guidelines recommend that all adults with HIV infection be treated, with no CD4 cell count threshold for initiating therapy. Initial regimens include a combination of nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors.
Researchers found that T-bet and RORα proteins enforce specific classes of memory B cells, which can produce antibodies against various infections. This discovery opens the way for developing vaccines that induce long-term immunity towards desired antibody classes.
A study published in JAMA found that using bone marrow cells to treat chronic ischemic heart failure did not show significant improvements in most measures of heart function. However, exploratory analysis revealed a significant effect on left ventricular ejection fraction (LVEF) among patients under 62 years old.
Researchers found that rituximab, a monoclonal antibody, was safe and effective in reducing liver damage in PBC patients who had an incomplete response to UDCA therapy. The study showed significant reductions in alkaline phosphatase levels and anti-mitochondrial antibodies after treatment.
Researchers studied the role of immune responses in oncolytic adenovirus therapy and found that CD8+ T cells mediate antitumor efficacy. The study proposes a new therapeutic regime combining oncolytic adenovirus with immunotherapy.
Researchers at UCLA have identified dihydromyricetin as a potential treatment for acute alcohol intoxication and withdrawal symptoms. The compound blocks the action of alcohol on the brain's GABAA receptors, reducing voluntary consumption without major side effects.
A study of over 26,000 patients found that therapeutic hypothermia was used in only 0.35% of out-of-hospital cardiac arrest cases in the US. Despite its proven benefits in reducing mortality and improving neurologic outcomes after a heart attack, hypothermic therapy is not being widely adopted in clinical practice.
Researchers at the Weizmann Institute have developed a new form of adoptive cell transfer that overcomes limitations of current therapies. This approach uses a donor pool of immune T cells prepared in advance, which are outfitted with receptors to specifically target and destroy tumors.
Researchers have identified a distinct population of immune cells that contribute to the pathogenesis of type 1 diabetes by helping CD8+ T cells elicit autoimmune responses in the pancreas. This subset of CD4+ T cells produces IL-21 and express CCR9, playing a critical role in autoimmune disease.
University of Cincinnati researchers have successfully produced large RNA nanoparticles using a bipartite approach, overcoming challenges in industry-scale production. The nanoparticles, containing small interfering RNA, show a half-life of between five and 10 hours in animal models, are non-toxic and produce no immune response.
Researchers have developed a cell therapy that selectively dampens vascular inflammation induced by LDL, showing substantial protective effects against atherosclerosis. The treatment has been shown to reduce the disease process by up to 70 percent in mouse studies.
For patients with confirmed high-grade dysplasia, endoscopic eradication therapy is recommended. Surveillance may be considered in some cases, but it is not a substitute for treatment. The American Gastroenterological Association recommends regular screening for cardiovascular risk factors and interventions.
Researchers discovered that activated T cells play a key role in IRIS, producing excessive interferon gamma and triggering an exaggerated immune response. A new animal model also confirmed the involvement of macrophages in sparking IRIS. These findings may lead to targeted prevention or therapy for HIV patients developing IRIS.
Scientists have developed a novel method to deliver therapeutic molecules, proteins, and DNA directly into living cells using laser-activated nanoparticles. The technique, which uses bursts of near-infrared light to create tiny holes in cell membranes, shows promise for gene-based therapies.
Researchers have identified eIF5A as a crucial player in pancreatic beta cell dysfunction in diabetes. Blocking hypusine modification of eIF5A protected mice in a model of diabetes, suggesting potential therapeutics for preserving beta cell function.
Researchers at Medical College of Georgia have identified a rare hybrid cell that can switch the immune system on or off, expressing indoleamine 2,3 dioxygenase to turn off T cells. This unique cell has properties of both dendritic and B cells, with potential implications for cancer and rheumatoid arthritis therapies.
Researchers have found that regulatory T cells slow down the immune response too soon, limiting vaccine effectiveness. By removing these cells, they discovered a two-fold increase in immune response to HIV vaccine.
Researchers at LSU Health Sciences Center have identified a novel mechanism that triggers brain damage during stroke, which they believe can be blocked using a high-potency reagent. This breakthrough may provide a new therapeutic target for stroke therapy, offering hope for patients affected by this devastating disease.
A new technique uses microscopic magnetic particles to target stem cells to sites of cardiovascular injury, resulting in a five-fold increase in cell localization and six-fold increase in cell capture. The method is directly applicable to clinical practice and could lead to the treatment of heart attacks and other vascular injuries usi...
Scientists discover a single transcription factor that can convert alpha cells into functional beta cells, increasing their number eight-fold in mice. The study shows promise for a potential new treatment for type I diabetes, where the body autodestructs beta cells leading to insulin deficiency and complications.
Researchers discovered a protein profile that may accurately predict tamoxifen resistance in breast cancer patients. The study found that the extracellular matrix metalloproteinase inducer (EMMPRIN) was significantly associated with an earlier tumor progression and poor clinical outcome.
A new study found that intermittent IL-7 therapy, combined with conventional antiretroviral therapy (c-ART), boosts the number of CD4+ and CD8+ T cells in HIV-infected patients with low T cell counts. This effect was observed for 48 weeks, suggesting a potential treatment option for these individuals.
A new study reveals that long-term non-progressors' immune cells can effectively contain HIV by stockpiling molecular weapons, enabling them to kill infected cells efficiently. The discovery advances understanding of the unique mechanisms behind this phenomenon and may inform the development of an HIV vaccine.
A phase II trial of Cybor-D, a combination therapy including cyclophosphamide, bortezomib, and dexamethasone, showed an improved response rate compared to traditional lenalidomide-dexamethasone therapy. The treatment resulted in a rapid initial decline and percentage reduction in M protein levels.
Two new studies provide insight into the molecular mechanisms underlying aberrant NF-κB activity in MM tumor cells. The research reveals diverse mutations that lead to pathological activation of NF-κB signaling in MM, highlighting its role as a target for therapy development.